Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Indrajit Choudhuri

Clinical Cardiac Electrophysiology Beloit, WI Medical Doctor

NPI 1467621110 CMS profile 203124

Beloit Health System INC, 1969 West Hart Road, Beloit, WI 53511

Open in the dashboard

General payments

$44,680

152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Indrajit Choudhuri of Beloit, WI is reported in the CMS Open Payments database as having received $44,680 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $736 31
2024 General $494 17
2023 General $339 9
2022 General $653 11
2021 General $943 15
2020 General $21,748 17
2019 General $19,766 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Indrajit Choudhuri
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Indrajit Choudhuri were reported at $736. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Indrajit Choudhuri Clinical Cardiac Electrophysiology median Middle half National median
2019 $19,766 $2,361 $585–$8,260 $163
2020 $21,748 $993 $247–$4,351 $114
2021 $943 $1,185 $326–$4,739 $132
2022 $653 $2,073 $554–$6,789 $149
2023 $339 $2,568 $759–$8,159 $160
2024 $494 $2,557 $703–$7,403 $164
2025 $736 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acutus Medical, Inc. $21,242 26 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $7,331 9 payments
  3. Biotronik Inc. $5,840 22 payments
  4. CardioFocus, Inc. $4,912 5 payments
  5. Janssen Pharmaceuticals, Inc $2,213 4 payments
  6. Atricure, Inc. $690 7 payments
  7. Biosense Webster, Inc. $459 15 payments
  8. Abbott Laboratories $424 11 payments
  9. Boston Scientific Corporation $320 7 payments
  10. E.R. Squibb & Sons, L.L.C. $266 13 payments
  11. Other $984 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $15,381 3 payments
  2. Travel and Lodging $11,922 23 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,068 6 payments
  4. Food and Beverage $6,179 117 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,050 2 payments
  6. Education $80 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $7,331 9 payments
  2. XARELTO $2,213 4 payments
  3. BioMonitor $425 5 payments
  4. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $385 3 payments
  5. Carto 3 $350 13 payments
  6. ATRICURE ATRICLIP LAA EXCLUSION $292 3 payments
  7. WATCHMAN Access System $245 3 payments
  8. SYNERGY ABLATION SYSTEM $242 2 payments
  9. ATRICLIP LAA EXCLUSION SYSTEM $213 2 payments
  10. Rivacor $188 3 payments
  11. Other $2,960 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

863

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$214,068

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

27.7%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 154 $170,732
Xarelto Rivaroxaban Brand 20 $19,474
Flecainide Acetate Generic 221 $11,513
Midodrine Hcl Generic 25 $2,906
Droxidopa Generic 25 $2,506
Amiodarone Hcl Generic 95 $1,793
Metoprolol Succinate Generic 102 $1,473
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 49 $1,465
Sotalol Sotalol Hcl Brand 16 $498
Fludrocortisone Acetate Generic 14 $492

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$71,544

Medicare's payments for the services billed

Medicare patients

306

Average age 77

Services billed

1,257

149 women, 157 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 63%
Heart failure 48%
Arthritis 46%
Ischemic heart disease 44%
Diabetes 32%
Chronic kidney disease 32%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $40
$40 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $40
$40 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $34
$34 20 —
Wegovy
  • Novo Nordisk Inc $26
$26 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record